683 Capital Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.51M Sell
150,000
-224,200
-60% -$10.6M 0.29% 67
2025
Q4
$19M Sell
374,200
-225,000
-38% -$11.5M 0.83% 25
2025
Q3
$33.2M Buy
599,200
+195,000
+48% +$11.4M 1.74% 14
2025
Q2
$27.9M Buy
404,200
+1,700
+0.4% +$116K 1.83% 14
2025
Q1
$27.9M Buy
402,500
+102,500
+34% +$8.47M 1.93% 13
2024
Q4
$25.8M Buy
+300,000
New +$32.4M 1.6% 15

Other funds holding NVO

683 Capital Management's NVO Position: Q1 2025 in Review

683 Capital Management sold out of Novo Nordisk (NVO) in Q1 2025, closing a stake of 60,000 shares — an estimated $4.96M sold.

683 Capital Management first reported a position in NVO in Q4 2024 and held it in 1 quarter. The position peaked at $5.16M in Q4 2024. 1,528 funds tracked by Wall St. Rank hold NVO as of Q1 2025.

  • 683 Capital Management reported no remaining Novo Nordisk position as of Q1 2025 after selling out during the quarter.
  • 683 Capital Management sold 60,000 Novo Nordisk shares in Q1 2025, an estimated $4.96M.
  • 683 Capital Management first reported a position in Novo Nordisk in Q4 2024 and held it in 1 quarter.
  • 683 Capital Management's Novo Nordisk position peaked at $5.16M in Q4 2024.
  • 1,528 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2025.

Based on 683 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.